A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01160861

Enrollment

Registered

2010-07-12

Start date

2010-07-11

Completion date

2011-04-30

Last updated

2022-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Brief summary

This is a Phase Ib, randomized, blinded, placebo-controlled, multiple-ascending dose study in patients with seasonal or perennial allergic rhinitis to investigate the safety, tolerability, and pharmacokinetics (PK) of MEMP1972A.

Interventions

DRUGMEMP1972A

Repeating ascending dose

DRUGplacebo

Repeating ascending dose

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of allergic rhinitis * In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs * Males or females who are surgically sterilized, post menopausal for the past year, or are using two acceptable methods of contraception against pregnancy through at least 6 months after the dose of study drug

Exclusion criteria

* History or clinical manifestations of significant metabolic, hepatic, renal, hematologic, immunodeficiency, pulmonary, cardiovascular, gastrointestinal, urologic, neurologic, or psychiatric disorders * History of anaphylaxis, hypersensitivity or drug allergies * Use of a non-biologic investigational drug or participation in an investigational study with a non-biologic drug within 30 days prior to dosing * Use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 3 months prior to dosing * Positive blood test for chronic viral infections by: hepatitis B surface antigen, hepatitis C virus antibody, or HIV antibody

Design outcomes

Primary

Measure	Time frame
Incidence and nature of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results	Throughout study or until early discontinuation
Incidence, nature, and severity of adverse events	Throughout study or until early discontinuation

Secondary

Measure	Time frame
Pharmacokinetic parameters of MEMP1972A (maximum plasma concentration, total serum clearance, volume of distribution, half-life)	Throughout study or until early discontinuation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026